Citi raised the firm’s price target on Alnylam Pharmaceuticals to $237 from $233 and keeps a Buy rating on the shares. The company’s net product revenue for Q4 narrowly beat estimates, the analyst tells investors in a research note. The firm says Alnylam’s growth in patient numbers remain steady across all approved products, which bodes well for sales in in fiscal 2024 and beyond.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ALNY:
- The Smid-cap biotech stocks to own in 2024, according to Bernstein
- Alnylam price target raised to $220 from $216 at Bernstein
- William Blair sees ATTR-PN market as large enough for two players
- Citi says approval ‘likely’ for Ionis’ eplontersen ATTR-PN NDA
- Alnylam price target raised by $7 at Piper Sandler, here’s why
